Pharma-Bio Serv, Inc. (PBSV)
| Market Cap | 33.62M |
| Revenue (ttm) | 21.56M |
| Net Income (ttm) | 2.05M |
| Shares Out | 23.00M |
| EPS (ttm) | 0.09 |
| PE Ratio | 16.52 |
| Forward PE | n/a |
| Dividend | $0.08 |
| Dividend Yield | 5.10% |
| Trading Day | March 5 |
| Last Price | $1.47 |
| Previous Close | $1.47 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 1.47 |
| Day's Range | 1.47 - 1.47 |
| Day's Volume | 1,009 |
| 52-Week Range | 0.5868 - 1.87 |
News
DORADO, PUERTO RICO / ACCESSWIRE / January 5, 2021 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support c...
Pharma-Bio Serv is a cheap stock based on EV/EBIT with good earnings quality based on various multi-year metrics.
About PBSV
Pharma-Bio Serv operates as a compliance and technology transfer services consulting firm. It provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products in Puerto Rico, the United States, Europe, and Brazil. The company's technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. Pharma-Bio Serv, Inc. was founded in 1993 and is headquartered in Dorado, Puerto Rico.
| Industry Health Information Services | Founded 1993 |
| CEO Victor Sanchez | Employees 220 |
| Stock Exchange OTCMKTS | Ticker Symbol PBSV |
Financial Performance
In 2020, PBSV's revenue was $21.56 million, an increase of 10.55% compared to the previous year's $19.51 million. Earnings were $2.05 million, a decrease of -1.74%.
Analyst Forecasts
The average 12-month stock price forecast for PBSV is 1.95, which is an increase of 32.65% from the latest price.